UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000005376
Receipt No. R000006380
Scientific Title Comparison of effect of sitagliptin and nateglinide on postprandial glucose level and secretion of insulin and glucagon after meal tolerance test in early type 2 diabetes
Date of disclosure of the study information 2011/04/04
Last modified on 2012/06/02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Comparison of effect of sitagliptin and nateglinide on postprandial glucose level and secretion of insulin and glucagon after meal tolerance test in early type 2 diabetes
Acronym Comparison of effectiveness of glinide and DPP-4 inhibitor in early type 2 diabetes
Scientific Title Comparison of effect of sitagliptin and nateglinide on postprandial glucose level and secretion of insulin and glucagon after meal tolerance test in early type 2 diabetes
Scientific Title:Acronym Comparison of effectiveness of glinide and DPP-4 inhibitor in early type 2 diabetes
Region
Japan

Condition
Condition early type 2 diabetes
Classification by specialty
Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To comfirm the efficacy and safety of sitagliptin in comparison with nateglinide in early type 2 diabetes whose glycemic control is insufficiet with diet and exercise therapy.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes To clarify which drug show more effective on glucose lowering after meal test between sitagliptin and nateglinide in the same patients?
How each drug influences on insulin, glucagon or other glucose regulation hormones' secriton.
Key secondary outcomes To clarify the effect of each drug on inflammatory cytekine level after the treatent
To comfirm frequency of hypoglycemia after the treatment

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration Institution is not considered as adjustment factor.
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 one dose of 100mg of sitagliptine
Interventions/Control_2 one dose of 90mg of nateglinide
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria the patients whose HbA1c level is more than 6.5% even after diet, excise.
1.the patients whose HbA1c are between 6.5 % and 8.0%.
2.the patients whose fasting glucose is less than 140 mg/dL.
3.the patients who have already started diet and exercise therapy for more than 3 months.
4.patients who are more than 20 year-old.
5.no restriction on sex
6.the patients who are able to read and understand the written informed consent.
Key exclusion criteria 1) type 1 diabetes
2) patients who has been prescribed oral hypoglycemic agents
3) patients who have serious liver disease (AST and/or ALT are more than 100IU/L)
4) patients who have serious kidney disease (Serum Cr is more than 2.0mg/dL)
5) patients who have serious heart disease ( patients who have apparent heartfailure or myocardial infarction within 3 months)
6) patients who have serious pancreatic disease
7) patients with cancer
8) anemic patients (Hb is less than 11g/dL)
9) patients with thrombocytepenia (Platelet count is less than 100000/mm3)
10) patients with serious diabetic complications including progressed neutopathy and proliferative retinopathy
11) patietns with serious infection, inflammation, or injuary. pre- or post- operative state
12) patients who have inflammatory bowel disease, ulcer in bowel, ileus and high risk for ileus
13) patinets with chronic bowel diseases which have probability to induce malabsorption syndrome
14) patients who has the disease which is deteriorated with increase of gas in bowel
15) heavy alcohol drinker (patients who drink more than 480mL of Japanese Sake, 2L of beer, 180mL of whisky, 360mL of wine, or 360mL of Shochu per day)
16) patients who are pregnant, hope to be pregnant, or are in lactation period
17) patients who have viral infection (HBV,HCV)
18) patients who are not applicable to this study judged by the medical doctor.
Target sample size 20

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takahisa Hirose M.D. and Ph.D
Organization Juntendo University Graduate School of Medicine
Division name Department of Metabolisma and Endocrinology
Zip code
Address 2-1-1 Hongo Bunkyo-ku Tokyo
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization Juntendo University Graduate School of Medicine
Division name Department of Metabolism and Endocrinology
Zip code
Address
TEL 03-5802-1579
Homepage URL
Email

Sponsor
Institute Juntendo University Graduate School of Medicine
Institute
Department

Funding Source
Organization none
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2011 Year 04 Month 04 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2010 Year 05 Month 11 Day
Date of IRB
Anticipated trial start date
2010 Year 06 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2011 Year 04 Month 04 Day
Last modified on
2012 Year 06 Month 02 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006380

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.